Get more information on Real-Time PCR (qPCR) Market - Request Sample Report
The Real-Time PCR (qPCR) Market Size was valued at USD 6.84 billion in 2023 and is expected to reach USD 10.30 billion by 2032 and grow at a CAGR of 4.67% over the forecast period 2024-2032.
The real-time PCR (qPCR) market is promising with the growing incidence of genetic disorders, infectious diseases, as well as chronic diseases. According to the CDC, congenital heart defects occur in approximately 1 percent of U.S. births yearly, thus a big demand for early detection and intervention through advanced diagnostics like qPCR. The critical need for PCR techniques applied to detect genetic variations for prenatal testing as well as diagnosis and prevention of diseases such as HIV, HPV, Alzheimer's, and Parkinson's disease is expanding the market. For instance, many European countries experienced an increase in invasive group A streptococcal (GAS) infections in children during the season of 2022-2023, leading to an increased demand for PCR-based diagnostics.
Other advantages of Real-Time PCR (qPCR) include precision, automation, accuracy, and real-time quantification, which have contributed to its rising adoption in various fields. This global trend is reflected in the substantial investments and initiatives aimed at enhancing qPCR capabilities in multiple countries. For instance, in 2023, the World Health Organization (WHO) launched a global initiative aimed at improving molecular diagnostics, specifically qPCR testing, in low- and middle-income countries. The program, funded by a USD 50 million investment, seeks to bolster healthcare infrastructure and increase testing capacities for infectious diseases like tuberculosis, HIV, and COVID-19. This initiative underscores the critical role that qPCR plays in public health surveillance and response. Additionally, in the United States, the Centers for Disease Control and Prevention (CDC) has allocated over USD 100 million to support the development and implementation of advanced qPCR technologies for various infectious diseases. This funding aims to enhance the country’s testing capabilities, especially in the context of emerging health threats.
Despite these advantages, other comparable technologies would exist to challenge its market. Technologies like immunoassays and next-generation sequencing will offer cheaper options with quick turnaround, thus competing with dPCR. Regulation is also a challenge for the industry, as the FDA U.S. has planned for regulation on laboratory-developed tests, LDTs. High-priced reagents and instruments for PCR, with some automated dPCR instruments reaching USD 100,000 also act as points of competition that prevent the adoption in the lower-budget research areas of regions.
However, high-tech innovations, such as ultrafast PCR technology that can run assays within 5 minutes, and strategic partnerships, such as the one between BD and CerTest Biotec for PCR assays, will continue to drive market growth. The qPCR market will grow steadily with the increasing trend of progress in PCR technology and explosive growth in POC testing requirements.
Drivers
Global Real-Time PCR (qPCR) Market Expansion Driven by Rising Genetic Disorders and Technological Advancements
One of the major contributors to the growth of the real-time PCR (qPCR) market is the increasing incidence of genetic disorders and life-threatening infectious diseases. Some of the other factors that continue to fuel this expansion are the growing incidence of genetic disorders, the increasing use of biomarker profiling in diagnostics, and the successful completion of the Human Genome Project. With advanced technology in PCR and investments, funding, and grants, the adoption of dPCR and qPCR will increase. These technologies prove very effective in diagnosing and evaluating disease-causing microbes, especially those that target.
Another critical driver of the market growth is the shift of focus towards genome-based drug discovery and away from plant-based treatments. This is notable in emerging markets with rising market penetration and consumer acceptance of genome-driven diagnostics and therapeutics. This is going to form a massive market for the technology. Technological limitations and the high cost of PCR instruments can turn out to be constraints on further expansion of the market.
Regulatory support has been the driving force in the advancement of PCR technologies. For instance, the U.S. FDA approved Bio-Rad's SARS-CoV-2 ddPCR Kit Emergency Use Authorization in 2020, while underlining PCR as an essential tool in fighting the COVID-19 pandemic. Moreover, Governments, as well as federal agencies of all countries, target qPCR and dPCR technologies within genomics research; this is backed by financial initiatives in both the public and private sectors. Due to this wide support, the growth of the global real-time PCR (qPCR) market is anticipated to accelerate.
Restraint
High Cost of Instruments and Consumables
Technological Limitations and Complexity
By Product
Reagents & Consumables were the leading product area in 2023 and more than 55.0% of the overall market share. The leading position of this product area is due to regular and repeat use of consumables during qPCR. These reagents and consumables have become indispensable for routine tests at diagnostic and research levels, hence ensuring continuous demand. Increased usage in disease diagnosis, particularly with infectious diseases, further accelerated the leading position of this segment. As far as the near future is concerned, the Software & Services segment is expected to be the most promising one. This growth would be a result of increased requirements for high-performance data analytics, PCR workflow automation, and improved in-lab operational efficiency. Therefore, the increased adoption of advanced PCR technologies in laboratories will be bound to accelerate the demand for integrated software solutions and maintenance services.
By Application
As of 2023, over 60.0% of market share in clinical applications was represented by the qPCR. The increasing prevalence of infectious diseases, genetic disorders, and cancer has also spurred the utilization of qPCR technology in clinical diagnostics. Its high accuracy, sensitivity, and speed in detecting and quantifying pathogens and genetic mutations make it an important tool for healthcare providers in making diagnoses and management decisions in clinical settings.
The fastest growth in this forecast period will be seen in the application segment of forensics. This growth can be due to increased dependence upon the use of qPCR for DNA sample analysis in criminal investigations, paternity testing, and disaster victim identification. Given the sensitivity and specificity of PCR in even minute and degraded samples, it has thus become an essential tool in forensic science and has witnessed rapid adoption.
By End-User
The Hospitals & Diagnostic Centers dominated the market in 2023, with a market share above 40.0%. Enhanced demand for accurate and rapid diagnostic solutions, especially during the ongoing management of infectious diseases and chronic illnesses, has furthered the cause of qPCR in these settings. Such ubiquity in hospitals and diagnostic labs worldwide is well facilitated by their seamless integration within routine diagnostic workflows. Pharmaceutical & Biotechnology Companies are the largest and fastest-growing end-user segment, primarily due to higher adoption of qPCR in drug discovery, development, and clinical trials. The trend towards personalized medicine and genome-based drug research has, of late, resulted in increasing adoption of qPCR technologies for evaluating genetic markers and developing targeted therapies. This trend is likely to persist since the pharmaceutical sector integrates genomics in most of its research and development work.
North America was the market leader in real-time PCR (qPCR) globally in 2023, holding more than 35.9% share of total revenue share. Growth in the region is attributed to increasing chronic disease incidences, genetic disorders, and infectious diseases, along with high demand for rapid diagnostic tests and a rising aging population. U.S. According to the Census Bureau, over 16.9 percent of the population of the United States, which sums up to as much as 56 million people, have aged above 65 years. As a result, this demographic trend tends to enhance the demand for diagnostics because older populations also appear to be at a higher risk of age-related and chronic conditions. North America also boasts of investments going into gene-based research. The presence of major market players such as Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., and Agilent Technologies, which is trying to shape the market with innovative solutions, further strengthens the market.
Asia Pacific is the most promising and lucrative market for qPCR. The growth in this region is valued by high unmet clinical needs, untapped market opportunities, and increasing health expenditure. Furthering the support for market expansion is the rising demand for advanced healthcare solutions, as well as governmental initiatives in the public health infrastructure. Such factors as target diseases, including both infectious and chronic conditions, and increased investments in health technologies, have led to the adoption of real-time, digital, and end-point PCR technologies.
Europe also holds a substantial market share in the qPCR market and is likely to do so in the future based on increasing diagnostics that are gene-based, infectious diseases are relatively common, and there is a very robust regulatory framework to support diagnostics technology development. Large countries like the U.K., Germany, and France are investing heavily in innovation in health care, which drives the regional market even further.
Need Any Customization Research On Real-Time PCR (qPCR) Market - Inquiry Now
Reagents & Consumables
Abbott
Agilent Technologies, Inc.
Thermo Fisher Scientific, Inc.
GE Healthcare
bioMérieux
F. Hoffmann-La Roche Ltd
Fluidigm Corporation
Takara Bio Inc.
TOYOBO Inc.
Instruments
Abbott
Bio-Rad Laboratories Inc.
Agilent Technologies, Inc.
Thermo Fisher Scientific, Inc.
GE Healthcare
Fluidigm Corporation
F. Hoffmann-La Roche Ltd
Lumex Instruments
Analytik Jena AG
Software & Services
Agilent Technologies, Inc.
Bio-Rad Laboratories Inc.
Thermo Fisher Scientific, Inc.
QIAGEN
Fluidigm Corporation
Primerdesign Ltd
B.D.
F. Hoffmann-La Roche Ltd
Recent Developments
In December 2023, Walgreens launched flu and COVID-19 testing services across the U.S., targeting the peak respiratory illness season.
In October 2023, MAWD Laboratories received Emergency Use Authorization (EUA) from the U.S. FDA for its COVID-19 PCR test.
In May 2023, Standard BioTools introduced the X9 High-Throughput Genomics System, enabling users to perform RT-PCR and NGS-based applications on a single benchtop system.
In April 2023, Curative, Inc. spun off Sensible Diagnostics, a company focused on commercializing a novel point-of-care (POC) PCR testing platform that delivers results within 10 minutes with high accuracy.
| Report Attributes | Details |
| Market Size in 2023 | US$ 6.84 billion |
| Market Size by 2032 | US$ 10.30 billion |
| CAGR | CAGR of 5.1% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Product (Reagents & Consumables, Instruments, Software & Services) • By Application (Clinical, Research, Forensics) • By End-User (Hospitals &Diagnostic Centers, Research Laboratories & Academic Institutes, Pharmaceutical & Biotechnology Companies, Clinical Research Organizations, Forensic Laboratories) |
| Regional Analysis/Coverage | North America (USA, Canada, Mexico), Europe (Germany, UK, France, Italy, Spain, Netherlands, Rest of Europe), Asia-Pacific (Japan, South Korea, China, India, Australia, Rest of Asia-Pacific), The Middle East & Africa (Israel, UAE, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Abbott, QIAGEN, Bio-Rad Laboratories Inc., Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., GE Healthcare, bioMérieux, F. Hoffmann-La Roche Ltd, Fluidigm Corporation, Takara Bio Inc., TOYOBO Inc., Lumex Instruments , Analytik Jena AG, Primerdesign Ltd , B.D. and other players |
| Key Drivers | • Global Real-Time PCR (qPCR) Market Expansion Driven by Rising Genetic Disorders and Technological Advancements |
| Market Restraints | • High Cost of Instruments and Consumables • Technological Limitations and Complexity |
Ans: The Real-Time PCR (qPCR) Market Size was valued at USD 6.84 billion in 2023.
Ans: The Real-Time PCR (qPCR) Market is to grow at a CAGR of 4.67% over the forecast period 2024-2032.
Ans: The Real-Time PCR (qPCR) test detects nucleic acid from a patient's samples who has Severe Acute Respiratory Syndrome Coronavirus 2. (SARS CoV-2).
Ans: Global Real-Time PCR (qPCR) Market Expansion Driven by Rising Genetic Disorders and Technological Advancements
Ans: • High Cost of Instruments and Consumables
• Technological Limitations and Complexity
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence (2023)
5.2 Prescription Trends, (2023), by Region
5.3 Device Volume, by Region (2020-2032)
5.4 Healthcare Spending, by Region, (Government, Commercial, Private, Out-of-Pocket), 2023
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Real-Time PCR (qPCR) Market Segmentation, by Product
7.1 Chapter Overview
7.2 Reagents & Consumables
7.2.1 Reagents & Consumables Market Trends Analysis (2020-2032)
7.2.2 Reagents & Consumables Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Instruments
7.3.1 Instruments Market Trends Analysis (2020-2032)
7.3.2 Instruments Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Software & Services
7.4.1 Software & Services Market Trends Analysis (2020-2032)
7.4.2 Software & Services Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Real-Time PCR (qPCR) Market Segmentation, by Application
8.1 Chapter Overview
8.2 Clinical
8.2.1 Clinical Market Trends Analysis (2020-2032)
8.2.2 Clinical Market Size Estimates and Forecasts to 2032 (USD Million)
8.3 Research
8.3.1 Research Market Trends Analysis (2020-2032)
8.3.2 Research Market Size Estimates and Forecasts to 2032 (USD Million)
Forensics
8.4.1 Forensics Market Trends Analysis (2020-2032)
8.4.2 Forensics Market Size Estimates and Forecasts to 2032 (USD Million)
9. Real-Time PCR (qPCR) Market Segmentation, by End User
9.1 Chapter Overview
9.2 Hospitals & Diagnostic Centers
9.2.1 Hospitals & Diagnostic Centers Market Trends Analysis (2020-2032)
9.2.2 Hospitals & Diagnostic Centers Market Size Estimates and Forecasts to 2032 (USD Million)
9.3 Research Laboratories & Academic Institutes
9.3.1 Research Laboratories & Academic Institutes Market Trends Analysis (2020-2032)
9.3.2 Research Laboratories & Academic Institutes Market Size Estimates and Forecasts to 2032 (USD Million)
9.4 Pharmaceutical & Biotechnology Companies
9.4.1 Pharmaceutical & Biotechnology Companies Market Trends Analysis (2020-2032)
9.4.2 Pharmaceutical & Biotechnology Companies Market Size Estimates and Forecasts to 2032 (USD Million)
9.5 Clinical Research Organizations
9.5.1 Clinical Research Organizations Market Trends Analysis (2020-2032)
9.5.2 Clinical Research Organizations Market Size Estimates and Forecasts to 2032 (USD Million)
9.6 Forensic Laboratories
9.6.1 Forensic Laboratories Market Trends Analysis (2020-2032)
9.6.2 Forensic Laboratories Market Size Estimates and Forecasts to 2032 (USD Million)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Real-Time PCR (qPCR) Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.2.3 North America Real-Time PCR (qPCR) Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.2.4 North America Real-Time PCR (qPCR) Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.2.5 North America Real-Time PCR (qPCR) Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.2.6 USA
10.2.6.1 USA Real-Time PCR (qPCR) Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.2.6.2 USA Real-Time PCR (qPCR) Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.2.6.3 USA Real-Time PCR (qPCR) Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.2.7 Canada
10.2.7.1 Canada Real-Time PCR (qPCR) Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.2.7.2 Canada Real-Time PCR (qPCR) Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.2.7.3 Canada Real-Time PCR (qPCR) Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.2.8 Mexico
10.2.8.1 Mexico Real-Time PCR (qPCR) Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.2.8.2 Mexico Real-Time PCR (qPCR) Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.2.8.3 Mexico Real-Time PCR (qPCR) Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3 Europe
10.3.1 Eastern Europe
10.3.1.1 Trends Analysis
10.3.1.2 Eastern Europe Real-Time PCR (qPCR) Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.3.1.3 Eastern Europe Real-Time PCR (qPCR) Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.1.4 Eastern Europe Real-Time PCR (qPCR) Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.3.1.5 Eastern Europe Real-Time PCR (qPCR) Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.1.6 Poland
10.3.1.6.1 Poland Real-Time PCR (qPCR) Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.1.6.2 Poland Real-Time PCR (qPCR) Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.3.1.6.3 Poland Real-Time PCR (qPCR) Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.1.7 Romania
10.3.1.7.1 Romania Real-Time PCR (qPCR) Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.1.7.2 Romania Real-Time PCR (qPCR) Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.3.1.7.3 Romania Real-Time PCR (qPCR) Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.1.8 Hungary
10.3.1.8.1 Hungary Real-Time PCR (qPCR) Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.1.8.2 Hungary Real-Time PCR (qPCR) Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.1.8.3 Hungary Real-Time PCR (qPCR) Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.1.9 turkey
10.3.1.9.1 Turkey Real-Time PCR (qPCR) Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.1.9.2 Turkey Real-Time PCR (qPCR) Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.3.1.9.3 Turkey Real-Time PCR (qPCR) Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.1.10 Rest of Eastern Europe
10.3.1.10.1 Rest of Eastern Europe Real-Time PCR (qPCR) Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.1.10.2 Rest of Eastern Europe Real-Time PCR (qPCR) Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.3.1.10.3 Rest of Eastern Europe Real-Time PCR (qPCR) Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2 Western Europe
10.3.2.1 Trends Analysis
10.3.2.2 Western Europe Real-Time PCR (qPCR) Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.3.2.3 Western Europe Real-Time PCR (qPCR) Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.2.4 Western Europe Real-Time PCR (qPCR) Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.3.2.5 Western Europe Real-Time PCR (qPCR) Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.6 Germany
10.3.2.6.1 Germany Real-Time PCR (qPCR) Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.2.6.2 Germany Real-Time PCR (qPCR) Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.3.2.6.3 Germany Real-Time PCR (qPCR) Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.7 France
10.3.2.7.1 France Real-Time PCR (qPCR) Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.2.7.2 France Real-Time PCR (qPCR) Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.3.2.7.3 France Real-Time PCR (qPCR) Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.8 UK
10.3.2.8.1 UK Real-Time PCR (qPCR) Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.2.8.2 UK Real-Time PCR (qPCR) Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.3.2.8.3 UK Real-Time PCR (qPCR) Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.9 Italy
10.3.2.9.1 Italy Real-Time PCR (qPCR) Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.2.9.2 Italy Real-Time PCR (qPCR) Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.3.2.9.3 Italy Real-Time PCR (qPCR) Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.10 Spain
10.3.2.10.1 Spain Real-Time PCR (qPCR) Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.2.10.2 Spain Real-Time PCR (qPCR) Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.3.2.10.3 Spain Real-Time PCR (qPCR) Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.11 Netherlands
10.3.2.11.1 Netherlands Real-Time PCR (qPCR) Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.2.11.2 Netherlands Real-Time PCR (qPCR) Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.3.2.11.3 Netherlands Real-Time PCR (qPCR) Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.12 Switzerland
10.3.2.12.1 Switzerland Real-Time PCR (qPCR) Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.2.12.2 Switzerland Real-Time PCR (qPCR) Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.3.2.12.3 Switzerland Real-Time PCR (qPCR) Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.13 Austria
10.3.2.13.1 Austria Real-Time PCR (qPCR) Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.2.13.2 Austria Real-Time PCR (qPCR) Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.3.2.13.3 Austria Real-Time PCR (qPCR) Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.14 Rest of Western Europe
10.3.2.14.1 Rest of Western Europe Real-Time PCR (qPCR) Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.2.14.2 Rest of Western Europe Real-Time PCR (qPCR) Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.3.2.14.3 Rest of Western Europe Real-Time PCR (qPCR) Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific Real-Time PCR (qPCR) Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.4.3 Asia Pacific Real-Time PCR (qPCR) Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.4.4 Asia Pacific Real-Time PCR (qPCR) Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.4.5 Asia Pacific Real-Time PCR (qPCR) Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4.6 China
10.4.6.1 China Real-Time PCR (qPCR) Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.4.6.2 China Real-Time PCR (qPCR) Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.4.6.3 China Real-Time PCR (qPCR) Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4.7 India
10.4.7.1 India Real-Time PCR (qPCR) Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.4.7.2 India Real-Time PCR (qPCR) Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.4.7.3 India Real-Time PCR (qPCR) Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4.8 Japan
10.4.8.1 Japan Real-Time PCR (qPCR) Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.4.8.2 Japan Real-Time PCR (qPCR) Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.4.8.3 Japan Real-Time PCR (qPCR) Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4.9 South Korea
10.4.9.1 South Korea Real-Time PCR (qPCR) Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.4.9.2 South Korea Real-Time PCR (qPCR) Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.4.9.3 South Korea Real-Time PCR (qPCR) Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4.10 Vietnam
10.4.10.1 Vietnam Real-Time PCR (qPCR) Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.4.10.2 Vietnam Real-Time PCR (qPCR) Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.4.10.3 Vietnam Real-Time PCR (qPCR) Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4.11 Singapore
10.4.11.1 Singapore Real-Time PCR (qPCR) Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.4.11.2 Singapore Real-Time PCR (qPCR) Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.4.11.3 Singapore Real-Time PCR (qPCR) Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4.12 Australia
10.4.12.1 Australia Real-Time PCR (qPCR) Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.4.12.2 Australia Real-Time PCR (qPCR) Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.4.12.3 Australia Real-Time PCR (qPCR) Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4.13 Rest of Asia Pacific
10.4.13.1 Rest of Asia Pacific Real-Time PCR (qPCR) Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.4.13.2 Rest of Asia Pacific Real-Time PCR (qPCR) Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.4.13.3 Rest of Asia Pacific Real-Time PCR (qPCR) Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5 Middle East and Africa
10.5.1 Middle East
10.5.1.1 Trends Analysis
10.5.1.2 Middle East Real-Time PCR (qPCR) Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.5.1.3 Middle East Real-Time PCR (qPCR) Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.5.1.4 Middle East Real-Time PCR (qPCR) Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.5.1.5 Middle East Real-Time PCR (qPCR) Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.1.6 UAE
10.5.1.6.1 UAE Real-Time PCR (qPCR) Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.5.1.6.2 UAE Real-Time PCR (qPCR) Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.5.1.6.3 UAE Real-Time PCR (qPCR) Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.1.7 Egypt
10.5.1.7.1 Egypt Real-Time PCR (qPCR) Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.5.1.7.2 Egypt Real-Time PCR (qPCR) Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.5.1.7.3 Egypt Real-Time PCR (qPCR) Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.1.8 Saudi Arabia
10.5.1.8.1 Saudi Arabia Real-Time PCR (qPCR) Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.5.1.8.2 Saudi Arabia Real-Time PCR (qPCR) Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.5.1.8.3 Saudi Arabia Real-Time PCR (qPCR) Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.1.9 Qatar
10.5.1.9.1 Qatar Real-Time PCR (qPCR) Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.5.1.9.2 Qatar Real-Time PCR (qPCR) Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.5.1.9.3 Qatar Real-Time PCR (qPCR) Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.1.10 Rest of Middle East
10.5.1.10.1 Rest of Middle East Real-Time PCR (qPCR) Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.5.1.10.2 Rest of Middle East Real-Time PCR (qPCR) Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.5.1.10.3 Rest of Middle East Real-Time PCR (qPCR) Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.2 Africa
10.5.2.1 Trends Analysis
10.5.2.2 Africa Real-Time PCR (qPCR) Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.5.2.3 Africa Real-Time PCR (qPCR) Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.5.2.4 Africa Real-Time PCR (qPCR) Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.5.2.5 Africa Real-Time PCR (qPCR) Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.2.6 South Africa
10.5.2.6.1 South Africa Real-Time PCR (qPCR) Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.5.2.6.2 South Africa Real-Time PCR (qPCR) Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.2.6.3 South Africa Real-Time PCR (qPCR) Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.2.7 Nigeria
10.5.2.7.1 Nigeria Real-Time PCR (qPCR) Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.5.2.7.2 Nigeria Real-Time PCR (qPCR) Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.5.2.7.3 Nigeria Real-Time PCR (qPCR) Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.2.8 Rest of Africa
10.5.2.8.1 Rest of Africa Real-Time PCR (qPCR) Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.5.2.8.2 Rest of Africa Real-Time PCR (qPCR) Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.5.2.8.3 Rest of Africa Real-Time PCR (qPCR) Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Real-Time PCR (qPCR) Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.6.3 Latin America Real-Time PCR (qPCR) Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.6.4 Latin America Real-Time PCR (qPCR) Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.6.5 Latin America Real-Time PCR (qPCR) Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.6.6 Brazil
10.6.6.1 Brazil Real-Time PCR (qPCR) Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.6.6.2 Brazil Real-Time PCR (qPCR) Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.6.6.3 Brazil Real-Time PCR (qPCR) Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.6.7 Argentina
10.6.7.1 Argentina Real-Time PCR (qPCR) Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.6.7.2 Argentina Real-Time PCR (qPCR) Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.6.7.3 Argentina Real-Time PCR (qPCR) Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.6.8 Colombia
10.6.8.1 Colombia Real-Time PCR (qPCR) Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.6.8.2 Colombia Real-Time PCR (qPCR) Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.6.8.3 Colombia Real-Time PCR (qPCR) Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.6.9 Rest of Latin America
10.6.9.1 Rest of Latin America Real-Time PCR (qPCR) Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.6.9.2 Rest of Latin America Real-Time PCR (qPCR) Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.6.9.3 Rest of Latin America Real-Time PCR (qPCR) Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11. Company Profiles
11.1 Abbott
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Products/ Services Offered
11.1.4 SWOT Analysis
11.2 QIAGEN
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Products/ Services Offered
11.2.4 SWOT Analysis
11.3 Bio-Rad Laboratories Inc.
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Products/ Services Offered
11.3.4 SWOT Analysis
11.4 Agilent Technologies, Inc.
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Products/ Services Offered
11.4.4 SWOT Analysis
11.5 Thermo Fisher Scientific, Inc.
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Products/ Services Offered
11.5.4 SWOT Analysis
11.6 GE Healthcare
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Products/ Services Offered
11.6.4 SWOT Analysis
11.7 bioMérieux
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Products/ Services Offered
11.7.4 SWOT Analysis
11.8 F. Hoffmann-La Roche Ltd
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Products/ Services Offered
11.8.4 SWOT Analysis
11.9 Fluidigm Corporation
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Products/ Services Offered
11.9.4 SWOT Analysis
11.10 Takara Bio Inc.
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Products/ Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segmentation
By Product
Reagents & Consumables
Instruments
Software & Services
By Application
Clinical
Research
Forensics
By End-User
Hospitals &Diagnostic Centers
Research Laboratories & Academic Institutes
Pharmaceutical & Biotechnology Companies
Clinical Research Organizations
Forensic Laboratories
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of the Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Product Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Product Matrix which gives a detailed comparison of the product portfolio of each company
Geographic Analysis
Additional countries in any of the regions
Company Information
Detailed analysis and profiling of additional market players (Up to five)
Genotyping Market was valued at USD 17.9 billion in 2023 and is expected to reach USD 59.31 billion by 2032, growing at a CAGR of 14.27% from 2024 to 2032.
The Scleral Lens Market size was valued at USD 319.78 Million in 2023 and is expected to reach USD 1197.36 Million By 2031 and grow at a CAGR of 15.8% over the forecast period of 2024-2031.
The Global Infection Surveillance Solutions Market was valued at USD 650.16 million in 2023 and is expected to reach USD 2010.88 million by 2032, growing at a CAGR of 13.39% over the forecast period 2024-2032.
The Healthcare Mobility Solutions Market Size was valued at USD 150.19 billion in 2023, and is expected to reach USD 1143.40 billion by 2032, and grow at a CAGR of 25.3% over the forecast period 2024-2032.
The Computer Vision in Healthcare Market Size was valued at USD 1.4 billion in 2023 and is expected to reach USD 49.0 billion by 2032 and grow at a CAGR of 47.8% over the forecast period 2024-2032.
The Vitrectomy Devices Market Size was valued at USD 1.19 billion in 2023, and will reach USD 1.89 billion by 2032, Growing at CAGR of 5.28% from 2024-2032.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
